ACPU
UTHR icon

Arrowgrass Capital Partners (US)’s United Therapeutics UTHR Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,000
Closed -$6.56M – 465
2015
Q3 		$6.56M Buy
50,000
+30,000
+150% +$4.81M 0.12% 132
2015
Q2 		$3.48M Buy
+20,000
New +$3.6M 0.05% 251
2015
Q1 		– Sell
-35,000
Closed -$4.53M – 522
2014
Q4 		$4.53M Buy
35,000
+15,000
+75% +$1.93M 0.08% 153
2014
Q3 		$2.57M Buy
+20,000
New +$2.06M 0.06% 165

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s UTHR Position: Q4 2015 in Review

Arrowgrass Capital Partners (US) sold out of United Therapeutics (UTHR) in Q4 2015, closing a stake of 50,000 shares — an estimated $6.56M sold.

Arrowgrass Capital Partners (US) first reported a position in UTHR in Q3 2014 and held it in 4 quarters. The position peaked at $6.56M in Q3 2015. 386 funds tracked by Wall St. Rank hold UTHR as of Q4 2015.

  • Arrowgrass Capital Partners (US) reported no remaining United Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 50,000 United Therapeutics shares in Q4 2015, an estimated $6.56M.
  • Arrowgrass Capital Partners (US) first reported a position in United Therapeutics in Q3 2014 and held it in 4 quarters.
  • Arrowgrass Capital Partners (US)'s United Therapeutics position peaked at $6.56M in Q3 2015.
  • 386 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2015, filed 16 Feb 2016.